We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

By LabMedica International staff writers
Posted on 10 Jul 2025

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. More...

Traditional testing methods can be slow, expensive, and require sending blood samples to a hospital laboratory, delaying treatment decisions. In particular, intensive care and emergency department settings often face challenges in quickly identifying high-risk patients for conditions such as sepsis. Now, a new study has demonstrated that nucleosomes, a key biomarker of immune disruption, can be quantified rapidly and simply using a lateral flow device, offering a potential solution to speed up diagnosis and enhance clinical decision-making.

VolitionRx’s (Henderson, NV, USA) Nu.Q nucleosome assay is a chemiluminescent immunoassay (ChLIA) that aids in the detection and evaluation of diseases associated with NETosis, a unique form of cell death. VolitionRx has developed a lateral flow device that quantifies nucleosomes directly from venous blood samples in minutes. The device was tested in a blinded study with blood samples from 25 hospital patients in intensive care and emergency departments. The study, part of the SUMMIT program, demonstrated the feasibility of using the lateral flow device for early detection of immune disruptions linked to conditions like sepsis.

The study showed that the device could be used to identify high-risk patients more efficiently. This breakthrough is expected to improve patient outcomes by enabling quicker clinical decision-making. The results correlated strongly with those of Volition's established automated central laboratory Nu.Q nucleosome assay, which is already used for disease monitoring. The device could be used in a doctor's office, emergency department, or intensive care setting, enabling the rapid identification of patients with immune disruptions without needing to send samples to a laboratory. The next phase of the SUMMIT program will focus on developing a capillary blood-based version of the test, with the goal of providing a finger-prick test for additional use cases.

"The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a simple lateral flow device could enable quicker clinical decision making and consequently better patient outcomes," said Gael Forterre, Chief Commercial Officer at VolitionRx. "This is a potential gamechanger, not only in diseases where time is critical such as sepsis, but also in providing our tests to lower-income countries where laboratory infrastructure may be weak or non-existent.”

Related Links:
VolitionRx


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Early and effective screening for gestational diabetes mellitus is becoming increasingly important (Photo courtesy of Shutterstock)

First-Trimester Blood Test Accurately Predicts Gestational Diabetes

Gestational diabetes mellitus (GDM) affects many pregnancies and is typically detected midway through pregnancy, often too late to prevent complications. Women diagnosed late face increased risks such... Read more

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.